Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

GRACEcast Cancer 101 Audio
17/07/2014 7 min
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

Listen "Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?"

Descargar episodio Ver en sitio original

Episode Synopsis

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

More episodes of the podcast GRACEcast Cancer 101 Audio

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy? 31/07/2014
Management of Rare Kidney Tumors 29/07/2014
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation? 27/07/2014
NanoString Treatment for Kidney Cancer 24/07/2014
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer? 22/07/2014
How is the Heng Criteria Applied to Kidney Cancer Patients? 20/07/2014
What is PD1 and PDL1 in Kidney Cancer? 15/07/2014
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope 13/07/2014
No Clear Answer for Non-Clear Cell Kidney Cancer 10/07/2014
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer 08/07/2014
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA